Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD9977 in Healthy Male Subjects
NCT02484729Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of balcinrenone in heart failure (HF) and chronic kidney disease (CKD) (3 arms), sponsored by AstraZeneca. Primary endpoints: Percentage of Participants With Adverse Events up to 45 days, Number of Participants With Clinically Significant Pulse Rate up to 45 days and 6 more. Started Jul 2015; status: completed.
02
Drugs
balcinrenone
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02484729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484729.